Beta interferon, NICE, and rationing

British Journal of General Practice

Volumn 52, Issue 482, 2002, Pages 784-785

  Kernick, David ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON;

COST EFFECTIVENESS ANALYSIS; DISABILITY; DRUG EFFICACY; DRUG USE; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE; HEALTH CARE NEED; HEALTH CARE POLICY; HEALTH SURVEY; HUMAN; MEDICAL DECISION MAKING; MULTIPLE SCLEROSIS; NATIONAL HEALTH SERVICE; PATIENT CARE; QUALITY OF LIFE; RELAPSE; REMISSION; REVIEW; UNITED KINGDOM;

EID: 0036769412     PISSN: 09601643     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (25)

1. Frankel S, Ebraihim S, Davey-Smith G. The limits to demand for healthcare. BMJ 2000; 321: 40-45.
2. New B. The rationing agenda in the NHS. BMJ 1996; 312: 1593-1601.
3. Department of Health press release. London, February 2002.
4. Butler J. The Ethics of Healthcare Rationing. London: Cassell: 1999.
5. Hunter D. Desperately Seeking Solutions, Rationing Healthcare. London: Longman, 1997.
6. Coast J. Rationing within The NHS should be explicit. The case against. BMJ 1997; 314: 118-122.
7. Taylor R, Mears R. Making rationing decisions at a national level at NICE. In: Kernick D (ed). Getting Health Economics Into Practice. Oxford: Radcliffe Press, 2002.
8. Multiple Sclerosis Society. Report on Market Research Findings. September 1999.
9. Donovan J, Coast J. Public preferences in priority setting - Unresolved issues. In: Malek M (ed). Setting Priorities in Healthcare. London: Wiley, 1994; 31-45.
10. Bowling A. Local Voices in Purchasing Healthcare. An Exploratory Exercise in Public Consultation in Priority Setting. London: King's Fund, 1993.
11. Goodkind D. Interferon beta therapy for multiple sclerosis. Lancet 352 (9139): 1483-1487.
12. Paty DW, Hartung HP, Ebers GC, et al. Management of relapsing-remitting multiple sclerosis: Diagnosis and treatment guidelines. Eur J Neurol 1999; 6: S1-S35.
13. NHS Executive. New Drugs for Multiple Sclerosis. [EL(1995/7).] London: Department of Health, 1995.
14. Beta Interferon and Glatirmer Acetete for the Treatment of Multiple Sclerosis. [NICE Technology Appraisal Guidance No 32.] London, 2002.
15. Gerard K, Mooney G. QALY league tables: Handle with care. Health Econ 1993; 2: 59.
16. Robinson R. Cost utility analysis. BMJ 1993; 307: 859-862.
17. Sacristan J, Bolanos E, Hernadez J, et al. Publication bias in health economic studies. Pharmacoecon 1997; 11(3): 289-290.
18. Stevens A, Colin-Jones D, Gabby J. Quick and clean: Authoritative health technology assessment for local healthcare contracting. Health Trends 1995; 27: 37-42.
19. Drummond M, Maynard A. Purchasing and Providing Cost-Effective Health Care. London: Churchill Livingstone, 1993; 103.
20. Cost-Effective Provision of Disease. Modifying Therapies for People with Multiple Sclerosis. [HSC 2002/004.] London: Department of Health, 2002.
21. World Health Organisation. European Healthcare Reforms: Analysis and Current Strategies. Copenhagen: WHO Regional Office for Europe, 1996.
22. Klein R. Priorities and rationing: Pragmatism or principles? BMJ 1995; 311: 761-762.
23. Honigsbaum F, Richards J, Lockett T. Priority Setting and Action: Purchasing Dilemmas. Oxford: Radcliffe Medical Press, 1995.
24. Lipsky M. Street Level Bureaucracy. New York: Russell Sage, 1980.
25. Weale A. Rationing health care. BMJ 1998; 316: 410.